CY1119393T1 - ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ - Google Patents

ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ

Info

Publication number
CY1119393T1
CY1119393T1 CY20171100947T CY171100947T CY1119393T1 CY 1119393 T1 CY1119393 T1 CY 1119393T1 CY 20171100947 T CY20171100947 T CY 20171100947T CY 171100947 T CY171100947 T CY 171100947T CY 1119393 T1 CY1119393 T1 CY 1119393T1
Authority
CY
Cyprus
Prior art keywords
trifluorothymidine
anticancer drug
drug containing
phosphorylation inhibitors
thymidine phosphorylation
Prior art date
Application number
CY20171100947T
Other languages
English (en)
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119393(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co., Ltd filed Critical Taiho Pharmaceutical Co., Ltd
Publication of CY1119393T1 publication Critical patent/CY1119393T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Παρέχεται θεραπευτικό φάρμακο κατά του καρκίνου ενισχυμένης αποτελεσματικότητας και ασφάλειας. Το θεραπευτικό φάρμακο κατά του καρκίνου είναι μία σύνθεση που περιέχει α, α, α-τριφθοροθυμιδίνη (FTD) και υδροχλωρική 5-χλωρο-6-(1-(2-ιμινοπυρρολιδινυλο)μεθυλ) ουρακίλη σε γραμμομοριακή αναλογία 1 : 0.5 και χορηγείται από του στόματος σε ασθενή που έχει ανάγκη σε δόση, ως δόση FTD, 20 έως 80 mg/m2/ημέρα, δύο έως τέσσερις φορές ημερησίως.
CY20171100947T 2005-01-26 2017-09-07 ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ CY1119393T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (1)

Publication Number Publication Date
CY1119393T1 true CY1119393T1 (el) 2018-02-14

Family

ID=36740357

Family Applications (2)

Application Number Title Priority Date Filing Date
CY2017029C CY2017029I1 (el) 2005-01-26 2017-09-07 ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ
CY20171100947T CY1119393T1 (el) 2005-01-26 2017-09-07 ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY2017029C CY2017029I1 (el) 2005-01-26 2017-09-07 ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ

Country Status (19)

Country Link
EP (1) EP1849470B2 (el)
JP (1) JP5576591B2 (el)
KR (1) KR101468216B1 (el)
AU (1) AU2006209547C1 (el)
CA (1) CA2594713A1 (el)
CY (2) CY2017029I1 (el)
DK (1) DK1849470T4 (el)
ES (1) ES2630002T3 (el)
FI (1) FI1849470T4 (el)
HU (2) HUE033306T2 (el)
LT (2) LT1849470T (el)
LU (1) LUC00036I2 (el)
NL (1) NL300889I2 (el)
PL (1) PL1849470T5 (el)
PT (1) PT1849470T (el)
RU (1) RU2394581C2 (el)
SI (1) SI1849470T2 (el)
TW (1) TWI362265B (el)
WO (1) WO2006080327A1 (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1849470B2 (en) 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
MX2012000369A (es) 2009-07-22 2012-02-01 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion.
MX2012000317A (es) 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PT2736495T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente à adulteração proporcionando libertação imediata de fármaco
LT2746404T (lt) 2011-08-16 2018-04-25 Taiho Pharmaceutical Co., Ltd. Priešvėžinis agentas ir terapinio poveikio prognozavimo būdas pacientams, sergantiems gaubtinės ir tiesiosios žarnos vėžiu su kras mutacija
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
AU2013233226B2 (en) 2012-03-14 2016-05-19 Nisshin Pharma Inc. Sulfur amino acid-containing composition
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2872526A1 (en) * 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
WO2014157443A1 (ja) * 2013-03-27 2014-10-02 大鵬薬品工業株式会社 イリノテカン塩酸塩水和物を含有する抗腫瘍剤
LT2979700T (lt) * 2013-03-27 2018-12-27 Taiho Pharmaceutical Co., Ltd. Priešnavikinis agentas, turintis mažą irinotekano hidrochlorido hidrato dozę
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
BR112015029616A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem resistente à adulteração com perfil de liberação bimodal
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
SI3042669T1 (sl) 2013-09-06 2023-07-31 Taiho Pharmaceutical Co., Ltd. Protitumorsko sredstvo in ojačevalec protitumorskega učinka
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CN107889459A (zh) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3693019A1 (en) * 2016-01-08 2020-08-12 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator
KR102412690B1 (ko) * 2016-02-05 2022-06-23 다이호야쿠힌고교 가부시키가이샤 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2191340C (en) * 1995-03-29 2001-04-17 Shingo Yano Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
DE69731940T2 (de) * 1996-09-24 2005-05-25 Taiho Pharmaceutical Co. Ltd. Uracilderivate enthaltende krebsmetastasen inhibitoren
EP1849470B2 (en) 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor

Also Published As

Publication number Publication date
RU2394581C2 (ru) 2010-07-20
PL1849470T5 (pl) 2024-06-10
AU2006209547C1 (en) 2022-04-07
JP5576591B2 (ja) 2014-08-20
ES2630002T3 (es) 2017-08-17
LT1849470T (lt) 2017-07-25
LTC1849470I2 (lt) 2019-10-25
AU2006209547B2 (en) 2011-05-26
CY2017029I2 (el) 2018-02-14
CA2594713A1 (en) 2006-08-03
EP1849470B1 (en) 2017-06-21
NL300889I1 (nl) 2017-08-14
DK1849470T3 (en) 2017-08-14
AU2006209547A1 (en) 2006-08-03
EP1849470A1 (en) 2007-10-31
KR20070104559A (ko) 2007-10-26
NL300889I2 (nl) 2018-01-16
PL1849470T3 (pl) 2017-11-30
JPWO2006080327A1 (ja) 2008-06-19
EP1849470B2 (en) 2024-03-20
TWI362265B (en) 2012-04-21
RU2007132181A (ru) 2009-03-10
LUC00036I2 (el) 2017-12-01
HUS1700032I1 (hu) 2017-09-28
HUE033306T2 (hu) 2017-11-28
PT1849470T (pt) 2017-09-22
WO2006080327A1 (ja) 2006-08-03
LUC00036I1 (el) 2017-10-02
LTPA2017024I1 (lt) 2017-08-10
KR101468216B1 (ko) 2014-12-03
EP1849470A4 (en) 2010-12-08
SI1849470T1 (sl) 2017-10-30
FI1849470T4 (fi) 2024-03-22
CY2017029I1 (el) 2018-02-14
TW200637562A (en) 2006-11-01
DK1849470T4 (en) 2024-04-02
SI1849470T2 (sl) 2024-05-31

Similar Documents

Publication Publication Date Title
CY1119393T1 (el) ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ
CY1123764T1 (el) Τετραϋδροβιοπτερινη για θεραπεια καταστασεων που σχετιζονται με αυξημενα επιπεδα φαινυλαλανινης
CY1118311T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας
AR109571A2 (es) Composición de trazodona para administración una vez por día
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
CY1115350T1 (el) Χρησεις αναστολεων της dpp iv
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
ECSP067068A (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA PARA LA INHIBICIÓN DE b-SECRETASA
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
NO20055880L (no) Memantin orale doseringsformer
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
SE0401342D0 (sv) Therapeutic compounds
TR200002969T2 (tr) Farmasötik bileşim.
CY1115973T1 (el) Συνδυασμος ινσουλινης με παραγωγα τριαζινης και χρηση αυτου για θεραπεια διαβητη
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CY1114686T1 (el) Χρηση toy ck2 αναστολεα για την θεραπεια και χημειοευαισθητοποιηση των ανθεκτικων σε αντικαρκινικα φαρμακα ογκων